TITLE:
Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers

CONDITION:
Anemia

INTERVENTION:
Placebo

SUMMARY:

      The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and minimum
      pharmacologically active dose of peginesatide in Healthy Volunteers.
    

DETAILED DESCRIPTION:

      This was a Phase 1, double-blind, placebo-controlled trial of peginesatide, an
      erythropoiesis stimulating agent, with approximately 7 treatment cohorts and 7 healthy
      volunteer participants per cohort. In each cohort of 7 participants, a ratio of 5:2
      participants was randomly assigned to receive a single dose of peginesatide or placebo,
      respectively, administered as an intravenous infusion. Planned peginesatide dose levels were
      to escalate by cohort. The study was conducted at a single clinical center.
    

ELIGIBILITY:
Gender: Male
Age: 18 Years to 40 Years
Criteria:

        Main eligibility criteria:

          -  Participant is a healthy male, age  18 years and  40 years, with body mass index
             (BMI)  18 and  30 kilograms per squared meter (kg/m^2), and weight  50 and  95
             kilograms (kg)

          -  Participant has hemoglobin of  16 grams per deciliter (g/dL) at the time of study
             entry

          -  Participant has normal iron stores
      
